Pricing Log in Create free account
Saturday 17 October 2026 Export PFE’s income statement to Excel — free account

Pfizer Inc.

PFE Healthcare Drug Manufacturers General

Pfizer Inc.’s revenue for fiscal 2025 (year ended December 2025) was $62.6 billion, down 1.65% from fiscal 2024. In the quarter to June 2026, revenue grew 2.60%, EPS fell 107.8%, free cash flow grew 125.2% and total debt rose 2.26%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for ten consecutive years; insiders bought in the last twelve months.

29.58 0.14 +0.48%
Market cap
$167.8B
P/E
38.9×
Fwd P/E
12.2×
Dividend yield
5.81%
F-score
6/9
Altman Z
2.03
Beneish M
−2.52
Dividend safety
28/100
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios Filings 10-Q 10-K

Pfizer Inc. (PFE) EV/EBITDA

Alert me on EV/EBITDA

As of 16 October 2026, Pfizer Inc. (PFE) trades at a EV/EBITDA of 10.8×. Over the past ten years it has ranged from 5.7× (March 2023) to 55.3× (July 2024); the current reading is higher than 30% of that period. That is below the Drug Manufacturers General industry median of 13.8× and above the Healthcare sector median of 9.2×.

EV/EBITDA, daily

Embed this chart

Annual newest first

Period EV/EBITDA Change
FY2025 9.2× (7.46%)
FY2024 10.0× (66.67%)
FY2023 30.0× 307.57%
FY2022 7.4× (46.42%)
FY2021 13.7× (23.50%)
FY2020 17.9× (10.33%)
FY2019 20.0× (11.06%)
FY2018 22.5× 95.72%
FY2017 11.5× (4.20%)
FY2016 12.0× (0.47%)

Quarterly newest first

Period EV/EBITDA Change
Jun 2026 9.3× (7.47%)
Mar 2026 10.0× 8.09%
Dec 2025 9.2× (1.45%)
Sep 2025 9.4× 8.86%
42 more quarters

Against its own ten years

Low 5.7× High 55.3×
Ten-year median 11.9×
Current reading's percentile 30

EV/EBITDA against peers

Company EV/EBITDA
NVO Novo Nordisk A/S compare 7.0×
GSK GSK PLC Sponsored ADR compare 9.3×
BMY Bristol Myers Squibb Company compare 10.2×
PFE Pfizer Inc. 10.8×
SNY Sanofi compare 11.1×
AZN AstraZeneca PLC compare 13.8×
NVS Novartis AG compare 14.5×
AMGN Amgen Inc. compare 16.8×
GILD Gilead Sciences, Inc. compare 829×
Drug Manufacturers General industry median 13.8×
Healthcare sector median 9.2×
Market median 11.0×

What EV/EBITDA is

Enterprise Value over EBITDA tells an investor how the market values a whole company, with debt added and cash taken off, against its operating earnings.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ EBITDA (TTM)

The full definition of EV/EBITDA →

More on PFE